RELATED STUDY
Therapeutic Use of Cannabis in Inflammatory Bowel Disease.
Key Findings: Cannabis use should be reserved for symptomatic control in patients with severe IBD refractory to the currently available standard-of-care and complementary and alternative medicines.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): United States
Year of Pub: 2016
Cannabinoids Studied: Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, GPCR, PPARs
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Citation: Ahmed W and Katz S. Therapeutic Use of Cannabis in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2016; 12:668-679.
Authors: Ahmed W, Katz S
